Receptor radionuclide therapy with 177Lu-DOTATATE in neuroendocrine tumours

被引：0
|
作者：
Bodei, L. [1 ]
Cremonesi, M. [1 ]
Grana, C. [1 ]
Bartolomei, M. [1 ]
Baio, S. [1 ]
Bufi, G. [1 ]
Fiorenza, M. [1 ]
Obenaus, E. [1 ]
Paganelli, G. [1 ]
机构：
[1] European Inst Oncol, Milan, Italy
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2006年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：S214 / S214
页数：1
相关论文
共 50 条
  • [21] A Care Process Model to Deliver 177Lu-Dotatate Peptide Receptor Radionuclide Therapy for Patients With Neuroendocrine Tumors
    Kasi, Pashtoon Murtaza
    Maige, Catherine L.
    Shahjehan, Faisal
    Rodgers, Jessica M.
    Aloszka, Debora L.
    Ritter, Ashton
    Andrus, Margaret L.
    Mcmillan, Jessica M.
    Mody, Kabir
    Sharma, Akash
    Jain, Manoj K.
    FRONTIERS IN ONCOLOGY, 2019, 8
  • [22] Renal and Hematological Toxicity in Patients of Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE
    Gupta, Santosh K.
    Singla, Suhas
    Bal, Chandrasekhar
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2012, 27 (09) : 593 - 599
  • [23] Understanding The Radiobiology Of Targeted Radionuclide Therapy With 177lu-dotatate
    Delbart, W.
    Wimana, Z.
    Vercruyssen, M.
    Meuleman, N.
    Ghanem, G.
    Flamen, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S13 - S14
  • [24] The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis
    Zhang, Jie
    Song, Qi
    Cai, Liang
    Xie, Ying
    Chen, Yue
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (06) : 1533 - 1543
  • [25] The efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with metastatic neuroendocrine tumours: a systematic review and meta-analysis
    Jie Zhang
    Qi Song
    Liang Cai
    Ying Xie
    Yue Chen
    Journal of Cancer Research and Clinical Oncology, 2020, 146 : 1533 - 1543
  • [26] Radiosensitivity of neuroendocrine cancer cells to 177Lu-DOTATATE and radiobiological implications for peptide radionuclide therapy
    Tamborino, G.
    Engbers, P.
    de Wolf, T.
    Reuvers, T.
    Konijnenberg, M.
    Nonnekens, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S66 - S66
  • [27] Biphasic exponential dosimetry model for 177Lu-DOTATATE peptide receptor radionuclide therapy
    Chen, Sirong
    Cheng, Kam
    Li, Ka Chun
    Leung, Yim Lung
    Cheung, William
    Wong, Ka Nin
    Wong, Yuet Hung
    Ho, Chi-Lai
    JOURNAL OF NUCLEAR MEDICINE, 2018, 59
  • [28] In-vivo stability of 177Lu-DOTATATE during peptide receptor radionuclide therapy
    Wilking, H.
    Ilan, E.
    Sandstrom, M.
    Andersson, C.
    Ost, A.
    Velikyan, I.
    Fross-Baron, K.
    Sundin, A.
    Lubberink, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S592 - S592
  • [29] Targeted Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE Alters Joints Inflammation
    Usmani, Sharjeel
    Rasheed, Rashid
    Ahmed, Najeeb
    Omar, Yehia
    Numani, Shah P.
    CLINICAL NUCLEAR MEDICINE, 2025, 50 (02) : e102 - e104
  • [30] Establishing a clinical dosimetry protocol for 177Lu-DOTATATE peptide receptor radionuclide therapy
    Bissell, S.
    Ross, E.
    McMeekin, H.
    Seal, E.
    Ogunwale, K.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S106 - S106
12345